Showing 3 posts of 3 posts found.


Novartis’ Xolair scores European approval to treat chronic rhinosinusitis with nasal polyps

August 6, 2020
Sales and Marketing Novartis, Xolair, rhinosinusitis

Novartis has snapped up approval from the European Commission for its anti-immunoglobulin E (IgE) antibody therapy Xolair (omalizumab) for the …


FDA approves Dupixent for chronic rhinosinusitis with nasal polyposis

June 27, 2019
Sales and Marketing Dupixent, FDA, Sanofi, US, pharma, rhinosinusitis

Regeneron Pharmaceuticals and Sanofi have revealed that their dual IL-4 and IL-13 inhibitor Dupixent (dupilumab) has secured FDA approval in …

Sanofi’s Dupixent improves symptoms in rhinosinusitis with nasal polyps at Phase 3

February 27, 2019
Research and Development Dupixent, Sanofi, pharma, rhinosinusitis

New data has been released on Sanofi’s Dupixent (dupilumab), derived from two Phase 3 trials, illustrating the drug’s efficacy In …

Latest content